By Dr Aaron Haubner (Senior Manager of North America Medical Affairs and Market Access at Terumo Blood 2025-06-05T09:00:43
Despite the promise of gene therapies, automated red blood cell exchange (aRBCX) remains an underutilised therapy in the management of sickle cell disease (SCD). In this article, Dr Aaron Haubner and Carly Newton of Terumo Blood and Cell Technologies, highlight the urgent need for partnerships and equitable access to this ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-07-10T09:00:00Z
2026-07-09T12:00:00Z
2026-07-08T12:00:00Z
2026-07-08T09:00:00Z
2023-02-02T11:05:15
Sponsored by Cell Signaling Technology
2023-03-07T10:55:58
Sponsored by Agilent
2023-09-27T10:36:50
Sponsored by NanoTemper Technologies
2023-01-20T14:24:55
Sponsored by Leica Microsystems
2023-03-23T14:46:21
Sponsored by Bio-Techne
2023-09-27T13:56:39
Sponsored by Euretos
Site powered by Webvision Cloud